Sep 2026· Journal of Visualized Experiments· Vol 235· 0 citations
Medicine
TL;DR
A narrative review evaluates what 'beyond fibrosis' should mean for risk assessment rather than treating fibrosis as dispensable and supports fibrosis-centered, layered risk stratification using clinical factors and noninvasive fibrosis measures.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly important cause of hepatocellular carcinoma (HCC). Fibrosis and cirrhosis remain the best-validated predictors of HCC, yet a substantial minority of MASLD-related tumors are diagnosed without cirrhosis. This narrative review evaluates what 'beyond fibrosis' should mean for risk assessment rather than treating fibrosis as dispensable. We first separate the proportion of HCC cases that are noncirrhotic from the much lower absolute incidence of HCC in the noncirrhotic MASLD population. We then synthesize human, animal, and in vitro evidence for lipotoxic and oxidative injury, insulin and insulin-like growth factor signaling, gut-liver communication, and immune remodeling. We distinguish plausible mechanistic drivers from clinical risk modifiers, future-risk biomarkers, early detection tests, and disease-modifying interventions. Current evidence supports fibrosis-centered, layered risk stratification using clinical factors and noninvasive fibrosis measures, whereas genetic, proteomic, microbial, and immune markers remain investigational. Resmetirom and semaglutide improve MASH histology in selected noncirrhotic patients with F2-F3 fibrosis; evidence for direct HCC prevention by metabolic drugs or bariatric surgery remains observational or absent. Routine surveillance is not justified for MASLD without advanced fibrosis, but individualized evaluation in F3 disease and prospective validation of multivariable risk models are priorities.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has overtaken viral hepatitis as the fastest-growing cause of hepatocellular carcinoma (HCC) in most high-income countries. What makes this epidemic clinically treacherous is a feature that distinguishes MASLD-related HCC from other aetiologies: roughly h...
L. Nevi, A. Altomare, P. Gallo et al.· Frontiers in Oncology· 1 citation
New evidence indicates that hepatic steatosis before and after sustained virologic response (SVR) is associated with suboptimal fibrosis regression and persistent HCC risk, highlighting the need for integrated clinical management incorporating metabolic optimisation and individualised surveillance.
M. El-Kassas, Abeer Awad, K. Al-Naamani et al.· Hepatoma Research· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become one of the most common chronic liver diseases worldwide, representing a major global health challenge closely linked to metabolic syndrome, obesity, and type 2 diabetes mellitus (TD2...
Damian Świerczek, Maja Dreger, Jakub Jatkowski et al.· International Journal of Mol...· 0 citations
Liver fibrosis is the common pathway through which chronic liver injury progresses to cirrhosis, portal hypertension, liver failure, hepatocellular carcinoma, and systemic complications. Its burden is increasing worldwide, driven mainly by metabolic dysfunction-associated steatotic liver disease, alcohol-related liver...
A. Lonardo, Mohamad Jamalinia, Ralf Weiskirchen· Livers· 0 citations
Promising histologic gains must now be translated into reduced morbidity and mortality through an ambitious agenda of long-term outcome trials, precision biomarkers, and equitable, multidisciplinary care models.
Zhi-Fu You, Ling-Long Yang, Yuan-Hao Long et al.· Frontiers in Pharmacology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.